Aquinox Pharmaceuticals Inc. (AQXP) Given Consensus Rating of “Buy” by Brokerages
Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) has earned an average recommendation of “Buy” from the six research firms that are covering the company. Two analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $20.60.
AQXP has been the subject of several research analyst reports. Jefferies Group boosted their price objective on Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the company a “hold” rating in a research report on Friday, August 5th. Zacks Investment Research lowered Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 9th. Canaccord Genuity set a $22.00 price objective on Aquinox Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, July 21st. Finally, Leerink Swann initiated coverage on Aquinox Pharmaceuticals in a research report on Tuesday, October 4th. They issued an “outperform” rating and a $24.00 price objective for the company.
In other news, major shareholder Bros. Advisors Lp Baker bought 2,783,605 shares of the business’s stock in a transaction on Tuesday, September 20th. The shares were purchased at an average price of $12.25 per share, for a total transaction of $34,099,161.25. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 3.00% of the stock is owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in shares of Aquinox Pharmaceuticals by 2.0% in the second quarter. Vanguard Group Inc. now owns 110,529 shares of the company’s stock worth $731,000 after buying an additional 2,197 shares in the last quarter. BlackRock Fund Advisors boosted its stake in shares of Aquinox Pharmaceuticals by 1.8% in the second quarter. BlackRock Fund Advisors now owns 228,693 shares of the company’s stock worth $1,514,000 after buying an additional 3,977 shares in the last quarter. BlackRock Advisors LLC boosted its stake in shares of Aquinox Pharmaceuticals by 2.1% in the second quarter. BlackRock Advisors LLC now owns 404,575 shares of the company’s stock worth $2,678,000 after buying an additional 8,280 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Aquinox Pharmaceuticals by 24.3% in the first quarter. BlackRock Inc. now owns 50,600 shares of the company’s stock worth $446,000 after buying an additional 9,900 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Aquinox Pharmaceuticals by 21.8% in the first quarter. Geode Capital Management LLC now owns 62,949 shares of the company’s stock worth $555,000 after buying an additional 11,268 shares in the last quarter. Hedge funds and other institutional investors own 65.87% of the company’s stock.
Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) traded down 0.54% during trading on Friday, reaching $11.02. The company’s stock had a trading volume of 128,784 shares. The company’s market cap is $189.68 million. The stock’s 50 day moving average price is $12.74 and its 200 day moving average price is $9.27. Aquinox Pharmaceuticals has a 52 week low of $6.01 and a 52 week high of $16.75.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.22. Equities research analysts predict that Aquinox Pharmaceuticals will post ($2.23) EPS for the current year.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.
Receive News & Stock Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.